Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Award
TOKYO, JAPAN and LEUVEN, BELGIUM – August 25th , 2020 – Tokyo-based Terumo Corporation (TSE: 4543) has today announced that Terumo Pharmaceutical Solutions has been awarded the Asia-Pacific Bioprocessing Excellence Award 2020 on July 7th at the Asia- Pacific Bio processing Excellence awards 2020.
It was the third year in a row for Terumo Pharmaceutical Solutions to win the award. The event for the year was held virtually owing to COVID-19.
Terumo Pharmaceutical Solutions was nominated in the category, ‘Best Bioprocessing Supplier Award: “Prefillable Syringes” and competed with several other established companies in the industry.
Ashit Sikka, Business Director, Terumo Pharmaceutical Solutions, India accepted this award on behalf of Terumo.
“We are very excited about the interest our PLAJEX™ platform continues to receive on the market and look forward to supporting our customer’s future requirements”, commented Marco Chiadò Piat, President, Terumo Pharmaceutical Solutions.
The Asia-Pacific Bioprocessing Excellence Award organized by IMAPAC, seeks to give recognition to exceptional biopr ocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, r educed cost and superior quality. Featuring top bioprocessing and biomanufacturing leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applaud extraordinary leaders & trend-setters of today, and inspire innovators of tomorrow.
An esteemed panel of expert judges and the Biologics Manufacturing Asia committee shortlisted the nominees that have proven to be outstanding in their respective categories. They include key opinion leaders with more than 20 years of experience, Process Development Vice Presidents and Directors, Heads of Manufacturing and bioprocessing from all the key players in both Asia and on a global level.
About Terumo Pharmaceutical Solutions
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.
Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, and primary packaging solutions.
Terumo Pharmaceutical Solutions has decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to the latest stages of product commercialization to optimize critical aspects of parenteral drug delivery.
About Terumo Europe:
Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and Cardio Vascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.
Please visit www.terumo-europe.com for more information.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.